/APGN

APGN Stock - Apexigen, Inc.

Q: What is the analyst price target for APGN?

Analyst price target information is not currently available for APGN.

Q: What is APGN's market cap?

Market capitalization information is not currently available for APGN.

Healthcare|Biotechnology|NASDAQ

$0.39+8.48%

+$0.03 (+8.48%) • Aug 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.42

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for APGN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta3.62

52W High$8.28

52W Low$0.33

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-32,686,000	$-28,957,000	$-24,544,000
Net Income	$-31,452,000	$-28,875,000	$-23,702,000
Net Margin	N/A	N/A	N/A
EPS	$-1.59	$-0.93	$-0.76

Company Overview

Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.

Visit Website

Earnings History & Surprises

APGN

Beat Rate

75%

Last 4 quarters

Avg Surprise

+74.0%

EPS vs Estimate

Beats / Misses

3/1

Last 12 quarters

Latest EPS

$0.24

Q3 2023

EPS Surprise History

Q4 21

No data

Q4 21

No data

Q2 22

No data

Q3 22

No data

Q4 22

+46.4%

$0.41vs$0.28

Q1 23

-8.3%

$0.33vs$0.36

Q2 23

+31.6%

$0.25vs$0.19

Q3 23

+226.3%

$0.24vs$-0.19

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2023	Nov 21, 2023	—	—	—	—
Q3 2023	Aug 10, 2023	$-0.19	$0.24	+226.3%	✓ BEAT
Q2 2023	May 17, 2023	$0.19	$0.25	+31.6%	✓ BEAT
Q1 2023	Feb 22, 2023	$0.36	$0.33	-8.3%	✗ MISS
Q4 2022	Nov 15, 2022	$0.28	$0.41	+46.4%	✓ BEAT
Q3 2022	Aug 18, 2022	—	$-224.74	—	—
Q2 2022	Apr 7, 2022	—	$-0.29	—	—
Q4 2021	Dec 31, 2021	—	$-0.26	—	—
Q4 2021	Oct 4, 2021	—	$-0.23	—	—
Q2 2021	Jun 30, 2021	—	$-9.06	—	—
Q1 2021	Mar 31, 2021	—	$-0.21	—	—
Q3 2020	Sep 30, 2020	—	$-0.00	—	—